会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明申请
    • PROCESS FOR OBTAINING ENANTIOMERS OF DULOXETINE PRECURSORS
    • 获得杜鹃素前体成分的方法
    • US20090247771A1
    • 2009-10-01
    • US12280084
    • 2007-02-27
    • Helmut Heinrich BuschmannAntoni Torrens JoverMatthias LormannStefan Dahmen
    • Helmut Heinrich BuschmannAntoni Torrens JoverMatthias LormannStefan Dahmen
    • C07D333/16
    • C07D333/24C07D333/12C07D333/14Y02P20/55
    • The present invention is directed to a process for the preparation of an enantiomerically enriched compound of formula II wherein, R1, R2 and R3 are each independently selected from hydrogen, halogen, substituted or unsubstituted lower alkyl or substituted or unsubstituted aryl; X is —C(═O)-Z or —Y, wherein —Y is selected from —CH2—OR4, —CH2-halogen or —CH2—NR6R7; wherein Z is selected from —NR6R7 or —OR5, wherein R5 is selected from hydrogen, substituted or unsubstituted lower alkyl or ester activating group; R4 is selected from hydrogen, hydroxyl protecting group or hydroxyl activating group; R6 and R7 are each independently selected from hydrogen, amino protecting group, amido protecting group or substituted or unsubstituted lower alkyl; or a pharmaceutically acceptable salt, complex or solvate thereof; which comprises an enantioselective addition with a thienyl zinc reagent, in the presence of a chiral ligand.
    • 本发明涉及制备对映体富集的式II化合物的方法,其中R 1,R 2和R 3各自独立地选自氢,卤素,取代或未取代的低级烷基或取代或未取代的芳基; X是-C(-O)-Z或-Y,其中-Y选自-CH2-OR4,-CH2-卤素或-CH2-NR6R7; 其中Z选自-NR 6 R 7或-OR 5,其中R 5选自氢,取代或未取代的低级烷基或酯活化基团; R4选自氢,羟基保护基或羟基活化基团; R6和R7各自独立地选自氢,氨基保护基,酰氨基保护基或取代或未取代的低级烷基; 或其药学上可接受的盐,复合物或溶剂化物; 其包括在手性配体存在下用噻吩锌试剂进行对映选择性加成。